• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . SARS-CoV-2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

tetano

Editor, Senior Moderator
J Med Virol


. 2026 Aug;98(8):e71067.
doi: 10.1002/jmv.71067.
SARS-CoV-2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

Federica Frasca[SUP] 1 2 [/SUP], Luca Maddaloni[SUP] 2 3 [/SUP], Alessandra D'Auria[SUP] 4 [/SUP], Matteo Fracella[SUP] 2 [/SUP], Ginevra Bugani[SUP] 4 [/SUP], Carmen Falvino[SUP] 3 [/SUP], Valentina Baccolini[SUP] 3 [/SUP], Giuseppe Migliara[SUP] 5 [/SUP], Francesca Aloisi[SUP] 2 [/SUP], Letizia Santinelli[SUP] 3 [/SUP], Enrico Palermo[SUP] 6 [/SUP], Luca Bortolani[SUP] 3 [/SUP], Alessandro Lazzaro[SUP] 3 [/SUP], Giancarlo Ceccarelli[SUP] 3 [/SUP], Ombretta Turriziani[SUP] 2 [/SUP], Claudio Maria Mastroianni[SUP] 3 [/SUP], Guido Antonelli[SUP] 2 7 [/SUP], Gabriella d'Ettorre[SUP] 3 [/SUP], Carolina Scagnolari[SUP] 2 6 [/SUP]


Affiliations
Abstract

This study examined changes in anti-Spike (anti-S) antibodies (Abs) and type I interferon (IFN-I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second dose (T2), and more than 1 year later (T3). Anti-S Abs were assessed by chemiluminescence and vesicular stomatitis virus (VSV)-based pseudo virus-neutralization assay, while IFN-α2, IFN-β, and IFN-ω mRNA levels were measured by RT-Real Time PCR. PLWH showed an increase in anti-S Immunoglobulin G (IgG) levels comparable to healthy donors (p < 0.001) and an induction of anti-S neutralizing Abs (p < 0.014 for T2 vs. T3). Age, gender, CD4[SUP]+[/SUP] T cell count, exposure to combined antiretroviral therapy (cART) and IFN-I levels at T0 did not affect the anti-S IgG production. IFN-I gene expression showed temporal changes, with a decrease at T2 (p < 0.01) and a subsequent increase at T3 (p < 0.001, for IFN-α2 and IFN-ω). A multivariable model revealed no overall change in the IFN-I response over time, except for IFN-β, which was lower at T3 than at T1 (p = 0.032). CD4[SUP]+[/SUP] T cell count was positively correlated with the IFN-I response (p < 0.05). These results suggest that mRNA vaccination can elicit an effective anti-S response and modulate the IFN-β gene expression in PLWH, with CD4[SUP]+[/SUP] T cell count being a key determinant of vaccine-induced changes in IFN.

Keywords: BNT162b2 COVID‐19 vaccine; HIV; anti‐Spike antibodies; interferon.

 
Back
Top